US Pharma MarketingThe post Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial appeared first on Clinical Trials Arena.
Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial
Amylyx acquired the PBH drug from Eiger BioPharmaceuticals during bankruptcy proceedings in 2024. The post Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial appeared first on Clinical Trials Arena .
Amylyx acquired the PBH drug from Eiger BioPharmaceuticals during bankruptcy proceedings in 2024.
Source: Clinical Trials Arena